- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Sun Pharmaceutical Industries Limited and Israel-based Moebius Medical Limited have published two articles in *Osteoarthritis and Cartilage*, focusing on MM-II, a novel non-opioid product for treating symptomatic knee osteoarthritis. The research highlights promising results from a Phase 2b trial, where a single MM-II injection provided meaningful pain relief for up to 26 weeks with a favorable safety profile. The second article details MM-II's mechanism of action, demonstrating its cartilage-protective effects by forming a lubricative layer over cartilage surfaces, potentially reducing degeneration. The data underscores MM-II's potential as an alternative to existing treatments, particularly amidst the opioid crisis. As the companies present new data at the OARSI 2025 World Congress, the positive outcomes could enhance Sun Pharma's position in the osteoarthritis market, valued at approximately $2 billion, and signal significant growth opportunities ahead. Investors should monitor developments closely, especially as Sun Pharma prepares for potential Phase 3 trials.
All announcements from Sun Pharmaceutical Industries Limited